Benzodiazepine use and risk of Alzheimer's disease: case-control study
I've been on clonazepam for more than a few months — given the unresolved question about benzodiazepines and dementia, is it worth working out a gradual tapering plan?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: Contested: the prospective Gray 2016 BMJ cohort found no dose-response link between benzodiazepine use and dementia, so reverse causation (early dementia symptoms leading to prescriptions) remains a live alternative explanation.
Comparing 1,796 older adults with Alzheimer's disease to 7,184 matched controls, past benzodiazepine use was associated with higher Alzheimer's risk, and the association strengthened with longer cumulative use — an association that cannot by itself prove the drugs cause dementia.
Worth asking
I've been on clonazepam for more than a few months — given the unresolved question about benzodiazepines and dementia, is it worth working out a gradual tapering plan?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Seizure disorders (Lennox-Gastaut syndrome, akinetic and myoclonic seizures; absence seizures unresponsive to succinimides)
- Panic disorder, with or without agoraphobia
Source
Benzodiazepine use and risk of Alzheimer's disease: case-control study — Billioti de Gage S, et al. (2014)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1136/bmj.g5205
DOI: 10.1136/bmj.g5205
How this was scored
- Study design
- Case-control study
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 8,980
- Preregistered
- No
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 72 out of 100 on our published rubric. One caveat travels with that badge: Contested: the prospective Gray 2016 BMJ cohort found no dose-response link between benzodiazepine use and dementia, so reverse causation (early dementia symptoms leading to prescriptions) remains a live alternative explanation. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Benzodiazepine use and risk of Alzheimer's disease: case-control study — Billioti de Gage S, et al. (2014). Published in: Top-tier peer-reviewed journal. DOI: 10.1136/bmj.g5205. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Case-control study. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is clonazepam (Klonopin, Rivotril), klonopin, rivotril FDA approved?
Yes — FDA approved for Seizure disorders (Lennox-Gastaut syndrome, akinetic and myoclonic seizures; absence seizures unresponsive to succinimides), Panic disorder, with or without agoraphobia. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.